To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

全球首家公布RSV候选疫苗与已获批重磅RSV疫苗头对头临床试验结果、且结果积极的厂家，来自中国。当开年至今无一款国产创新型疫苗获批上市，二类疫苗又几乎迎来全员内卷、“价格战”四处打响时，中国创新疫苗行业终于传来了一则好消息：一款国产呼吸道合胞病毒（R ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

冬季来临，呼吸道病毒频发，尤其是针对老年人的影响更为严重。你可曾想过，如何才能有效预防呼吸道合胞病毒（RSV）带来的健康威胁？近期，三叶草生物的二价RSV候选疫苗SCB-1019在临床试验中展现出积极的数据，可能为我们开启一条新的防疫之路。 RSV的危害与现状 呼吸道合胞病毒（RSV）是一种常见的病毒，主要引起婴幼儿及老年人的呼吸道感染。对于老年人来说，RSV感染不仅可以导致严重的肺炎，还可能引发 ...

智通财经APP讯，三叶草生物-B(02197)发布公告，在Ⅰ期临床试验中评估未使用佐剂的二价RSV ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.